Clinical Scorecard: SRSF1 Gene Delivery Extends Lifespan in Aged Mice
At a Glance
| Category | Detail |
|---|---|
| Condition | Age-related cellular decline and frailty |
| Key Mechanisms | SRSF1 encodes an RNA splicing factor. In human fibroblasts, its overexpression was associated with reduced cellular senescence, inflammatory signaling, and proteostatic stress, and restoration of DNA repair programs; the mechanisms linking RNA processing to these effects remain under investigation. |
| Target Population | Preclinical study of human fibroblasts and aged female mice |
| Care Setting | Preclinical research; findings have not established a clinical treatment for aging or frailty. |
Key Highlights
- A machine learning model trained on gene-expression data from 464 human fibroblast samples was used to screen candidate genes.
- SRSF1 overexpression produced the most consistent reduction in predicted transcriptomic age among the screened genes.
- In aged female mice, inducible SRSF1 delivery increased median lifespan from 778 to 886 days.
- Treatment reduced the rate of frailty accumulation by approximately 44% and delayed sustained frailty onset by 123 days.
- The study was preclinical and conducted in a small mouse cohort; expression timing and level affected observed outcomes.
Guideline-Based Recommendations
Diagnosis
Management
Monitoring & Follow-up
Risks
- Excessive expression of Yamanaka reprogramming factors can return mature cells to a pluripotent state and increase tumor risk.
- Constitutive SRSF1 overexpression did not improve skin repair or muscle regeneration, despite producing higher SRSF1 levels.
Patient & Prescribing Data
No human patients were treated. Experiments included human fibroblasts and aged female mice.
An inducible SRSF1 construct was delivered to aged mice using an adeno-associated viral vector that primarily targeted the liver. The findings are preclinical and do not establish a human dose, safety profile, or prescribing recommendation.
Clinical Best Practices
- Interpret the lifespan and frailty findings as results from a small preclinical mouse cohort, not as evidence of efficacy in humans.
- Distinguish inducible SRSF1 expression from constitutive overexpression; the article reports different outcomes.
- The researchers are still investigating how SRSF1-related RNA-processing changes produce the observed effects.
Related Resources & Content
This content is an AI-generated, fully rewritten summary based on a published scholarly article. It does not reproduce the original text and is not a substitute for the original publication. Readers are encouraged to consult the source for full context, data, and methodology.
